Joe Wiley, Amryt CEO

A biotech with a yen for pricey rare dis­ease drugs — and bar­gain base­ment shop­ping — adopts an­oth­er or­phan in lat­est M&A pact

Af­ter mak­ing it through a long, painful haul to get past a CRL and on to an FDA ap­proval last sum­mer, lit­tle Chi­as­ma has found a buy­er.

Am­ryt $AMYT, a com­pa­ny known for its ap­petite for ac­quir­ing ex­pen­sive drugs for rare dis­eases at bar­gain prices, snagged Chi­as­ma and its acromegaly drug My­capssa (oc­treotide) cap­sules in an all-stock deal — with an ex­change of 0.396 shares of Am­ryt for every share of Chi­as­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.